title: Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003.
abstract: To achieve the ultimate goal of cancer treatment, which is 100% cancer control with negligible toxicity, the therapeutic window must be enlarged, allowing for higher doses of beneficial treatments with reduced toxicity. The advent of image- and metabolism-guided therapy offers the best opportunity to date for combining modern radiation targeting and imaging techniques. Indeed, for the first time, it is reasonable to locally target metastatic disease with the goal of sterilization. Combining these focal radiation techniques with novel targeted antiproliferative agents and full-dose classic cytotoxic chemotherapy will become more effective as we learn to use these compounds in a less systemically toxic manner and as radiation fields become more defined. In addition, increasing numbers of biologic modifiers of normal tissue response are becoming available, and they suggest great promise for decreasing the normal tissue toxicity resulting from both radiation and chemotherapy treatments. Thus, radiation metastectomy for gross metastases, used together with systemic control of micrometastatic disease, may yield improved survival rates. This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain.
authors.affiliation: Department of Radiation Oncology, JP Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA. paul_okunieff@urmc.rochester.edu
authors.forename: Paul
authors.initials: P
authors.lastname: Okunieff
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Meyn
authors.forename: Beverly A
authors.initials: BA
authors.lastname: Teicher
authors.forename: Charles R
authors.initials: CR
authors.lastname: Thomas
authors.forename: Laurie E
authors.initials: LE
authors.lastname: Gaspar
authors.forename: David
authors.initials: D
authors.lastname: Raben
authors.forename: Shankar
authors.initials: S
authors.lastname: Giri
authors.forename: Robert S
authors.initials: RS
authors.lastname: Lavey
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Turrisi
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Swanson
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Smalley
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D018787:Radiation Oncology / Q000639:trends*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D011838:Radiation-Sensitizing Agents